Results 231 to 240 of about 15,263 (254)

Dupilumab for the treatment of asthma

Expert Opinion on Biological Therapy, 2017
Introduction Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma.
Alessandro Vatrella, Girolamo Pelaia, Rosario Maselli   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Dupilumab

Reactions Weekly, 2022
  +9 more sources

Dupilumab

Reactions Weekly, 2023
  +5 more sources

Dupilumab

Reactions Weekly, 2020
openaire   +2 more sources

Dupilumab

Reactions Weekly, 2018
  +5 more sources

Dupilumab

Reactions Weekly, 2021
  +5 more sources

Dupilumab

Reactions Weekly, 2019
  +4 more sources

The Role of Dupilumab in Severe Asthma

Biomedicines, 2021
Fabio Luigi Massimo Ricciardolo, Vitina Carriero, Francesca Bertolini   +2 more
exaly  

Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management

Expert Review of Respiratory Medicine, 2022
Marco Caminati, Pierluigi Paggiaro, Patrick Pintér   +2 more
exaly  

Rosacea associated with dupilumab therapy

Journal of Dermatological Treatment, 2021
Vivian Y Shi, Aleksi Hendricks
exaly